Onxeo announces positive DSMB recommendation for its Phase III trial with Livatag in primary liver cancer
26-Nov-2014 -
Onxeo SA announced that the European Independent Board of Experts (Data Safety and Monitoring Board, DSMB) in charge of the safety monitoring of the Livatag® Phase III trial has once again unanimously recommended continuing the study without modification."Each new positive recommendation from our ...
hepatocellular carcinoma
liver cancer
phase III studies